



This is a repository copy of *Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/134841/>

Version: Accepted Version

---

**Article:**

Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial). *British Journal of Haematology*, 185 (3). pp. 573-578. ISSN 0007-1048

<https://doi.org/10.1111/bjh.15551>

---

© 2018 British Society for Haematology and John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2018) Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial). *British Journal of Haematology*. ISSN 0007-1048, which has been published in final form at <https://doi.org/10.1111/bjh.15551>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.


**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.


**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.


Figure 1




Number at Risk  
46 44 36 25 19 14 9 8 5 1 1



Number at Risk  
1: ASCT (n=24) 24 24 23 22 21 19 17 15 14 7 4 2 2 1  
2: non-ASCT (n=22) 22 20 17 15 14 11 7 6 4 1 1 0 2 1



Number at Risk  
46 44 44 40 40 39 39 37 35 25 18 10 9 3 0



Number at Risk  
1: ASCT (n=24) 24 24 24 23 23 22 22 22 20 14 10 7 6 2 0  
2: non-ASCT (n=22) 22 20 20 17 17 17 17 15 15 11 8 3 3 1 0

Figure 2

